Pabalgesic (dextropropoxyphene + paracetamol): Uses, Dosage & Side Effects

What it's for (Indications)

Dextropropoxyphene and paracetamol combination products were historically indicated for the relief of mild to moderate pain.
This combination aimed to leverage the opioid analgesic properties of dextropropoxyphene with the non-opioid analgesic and antipyretic effects of paracetamol (acetaminophen), providing a dual-mechanism approach to pain management.
However, it is crucial to note that due to significant safety concerns, particularly related to cardiac toxicity and fatal overdose risk, dextropropoxyphene-containing products, including those combined with paracetamol, have been withdrawn from the market in many countries, including the United States, United Kingdom, and various European nations.
Therefore, while historically used for such pain, these indications are no longer considered appropriate or safe under current medical guidelines, and the drug is generally not available for prescription or use.

Dosage Information

Type	Guideline
Standard	Historically, the typical adult dosage for dextropropoxyphene and paracetamol combination products was usually one or two capsules or tablets every four hours as needed for pain, not exceeding a maximum daily dose. For instance, a common formulation might contain 65 mg of dextropropoxyphene hydrochloride or 100 mg of dextropropoxyphene napsylate combined with 325 mg or 650 mg of paracetamol. It is imperative to understand that due to severe safety risks, these dosage recommendations are now largely obsolete as the drug has been withdrawn from medical use in many regions. Administering this medication is no longer recommended due to the high potential for serious adverse events, including cardiotoxicity and fatal overdose, even within recommended therapeutic doses. Patients should never attempt to self-administer or acquire this medication.

Type

Guideline

Standard

Historically, the typical adult dosage for dextropropoxyphene and paracetamol combination products was usually one or two capsules or tablets every four hours as needed for pain, not exceeding a maximum daily dose. For instance, a common formulation might contain 65 mg of dextropropoxyphene hydrochloride or 100 mg of dextropropoxyphene napsylate combined with 325 mg or 650 mg of paracetamol. It is imperative to understand that due to severe safety risks, these dosage recommendations are now largely obsolete as the drug has been withdrawn from medical use in many regions. Administering this medication is no longer recommended due to the high potential for serious adverse events, including cardiotoxicity and fatal overdose, even within recommended therapeutic doses. Patients should never attempt to self-administer or acquire this medication.

Safety & Warnings

Common Side Effects

The combination of dextropropoxyphene and paracetamol could lead to a wide range of side effects, primarily due to the dextropropoxyphene component.
Common side effects associated with dextropropoxyphene included dizziness, sedation, nausea, vomiting, constipation, and lightheadedness.
More serious, dose-related central nervous system effects could manifest as confusion, disorientation, hallucinations, and seizures.
Cardiac toxicity, characterized by QTc prolongation, arrhythmias, and cardiac arrest, was a critical and often fatal concern, even at therapeutic doses, leading to the drug's market withdrawal.
Paracetamol, while generally well-tolerated at therapeutic doses, carries the risk of hepatotoxicity (liver damage), especially in overdose, with symptoms including nausea, vomiting, abdominal pain, and jaundice.
Hypersensitivity reactions, though rare, could also occur with either component.

Serious Warnings

Black Box Warning: **WARNING: SERIOUS CARDIAC TOXICITY AND FATAL OVERDOSE RISK** Dextropropoxyphene-containing products, including combinations with paracetamol, were associated with serious and potentially fatal cardiac toxicity, leading to their withdrawal from the market in the United States, Europe, and many other countries. These products were linked to significant risks of overdose, both intentional and accidental, which frequently resulted in death. The primary cardiac concern was the dose-dependent prolongation of the QT interval, which could lead to serious ventricular arrhythmias, including Torsades de Pointes, and subsequent cardiac arrest, even at doses only slightly exceeding the recommended therapeutic range. This risk was heightened in patients with pre-existing cardiac conditions, electrolyte disturbances, or those concurrently using other QT-prolonging medications. Furthermore, the central nervous system depressant effects of dextropropoxyphene, when combined with alcohol, benzodiazepines, or other CNS depressants, significantly increased the risk of severe respiratory depression, profound sedation, coma, and death. Patients should be explicitly warned against the use of any dextropropoxyphene-containing medication due to these severe, life-threatening risks. The combined risk of cardiac toxicity from dextropropoxyphene and severe hepatotoxicity from paracetamol in overdose further amplified the danger associated with this medication.
Numerous serious warnings were associated with the use of dextropropoxyphene + paracetamol, which ultimately led to its market withdrawal.
A primary concern was the significant risk of fatal overdose, which could occur with intentional or accidental ingestion, even slightly above recommended doses, and was exacerbated by co-ingestion of alcohol or other CNS depressants.
The cardiotoxic effects of dextropropoxyphene, including prolongation of the QTc interval and ventricular arrhythmias, posed a life-threatening risk.
Patients with pre-existing cardiac conditions or those taking other QT-prolonging drugs were particularly vulnerable.
Additionally, the paracetamol component carried a risk of severe hepatotoxicity, particularly with overdose or in patients with underlying liver disease or chronic alcohol use.
Respiratory depression, especially in elderly, debilitated, or opioid-naive patients, was another critical opioid-related warning.
Due to these profound safety concerns, this medication is no longer considered safe or appropriate for use.

How it Works (Mechanism of Action)

The analgesic action of the combination drug dextropropoxyphene + paracetamol is derived from two distinct pharmacological mechanisms. Dextropropoxyphene, a synthetic opioid, primarily acts as a weak mu-opioid receptor agonist in the central nervous system (CNS). By binding to these receptors, it inhibits the release of neurotransmitters involved in pain perception, thereby altering the perception of pain and increasing the pain threshold. Its analgesic potency is generally considered to be about half that of codeine. Paracetamol (acetaminophen), on the other hand, exerts its analgesic and antipyretic effects through different pathways, though its exact mechanism is not fully understood. It is believed to act primarily in the CNS by inhibiting prostaglandin synthesis, possibly via selective inhibition of cyclooxygenase-3 (COX-3), and by modulating serotonergic descending pain pathways. The combination was intended to provide additive analgesic effects, but the serious cardiac risks of dextropropoxyphene overshadowed its pain-relieving benefits.